Latent inhibition and its potential as a biomarker for schizophrenia
The biological heterogeneity of schizophrenia continues to be a major obstacle for clinical practice and the development of novel drug treatments. A non-invasive biomarker to define sub-groups of patients with common neurobiological underpinnings would dramatically improve detection, diagnosis and t...
Main Authors: | Kiri T. Granger, Anahita Talwar, Jennifer H. Barnett |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2020-12-01
|
Series: | Biomarkers in Neuropsychiatry |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2666144620300150 |
Similar Items
-
Effects of 7.5% Carbon Dioxide and Nicotine Administration on Latent Inhibition
by: Kiri T. Granger, et al.
Published: (2021-04-01) -
Inhibition of Return in Schizophrenia
by: Hinds, Jeffrey D. (Jeffrey Dale)
Published: (1996) -
Are NCAM deficient mice an animal model for schizophrenia?
by: Anne eAlbrecht, et al.
Published: (2012-07-01) -
The Use of Cognitive Screening in Pharmacotherapy Trials for Cognitive Impairment Associated With Schizophrenia
by: Jack Cotter, et al.
Published: (2019-09-01) -
Reduced Prepulse Inhibition as a Biomarker of Schizophrenia
by: Luis Gonzalo De La Casa, et al.
Published: (2016-10-01)